Subscribe
shutterstock_1983054248_jhvephoto
JHVEphoto / Shutterstock.com
12 May 2022Big PharmaMuireann Bolger

Israel targets Teva over MS drug royalties

The state of Israel has sued Teva Pharmaceuticals for $100 million over alleged unpaid royalties relating to its multiple sclerosis drug, Copaxone.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Otsuka says Teva’s REXULTI generic infringes patents
24 February 2022   Otsuka Pharmaceutical has sued Teva Pharmaceuticals, alleging that the company’s planned generic of Otsuka’s REXULTI antipsychotic (brexpiprazole) tablets infringe five of its patents.
Generics
Israel imports patented antivirals for treating COVID-19
24 March 2020   Israel has approved generic versions of an HIV antiviral owned by AbbVie for use in treating coronavirus, despite the company still holding patent protection and doubts over its effectiveness.
Biotechnology
Biotech wins $16.5 million in drug royalties dispute
18 October 2022   Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the multiple sclerosis drug elsewhere.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Otsuka says Teva’s REXULTI generic infringes patents
24 February 2022   Otsuka Pharmaceutical has sued Teva Pharmaceuticals, alleging that the company’s planned generic of Otsuka’s REXULTI antipsychotic (brexpiprazole) tablets infringe five of its patents.
Generics
Israel imports patented antivirals for treating COVID-19
24 March 2020   Israel has approved generic versions of an HIV antiviral owned by AbbVie for use in treating coronavirus, despite the company still holding patent protection and doubts over its effectiveness.
Biotechnology
Biotech wins $16.5 million in drug royalties dispute
18 October 2022   Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the multiple sclerosis drug elsewhere.

More on this story

Americas
Otsuka says Teva’s REXULTI generic infringes patents
24 February 2022   Otsuka Pharmaceutical has sued Teva Pharmaceuticals, alleging that the company’s planned generic of Otsuka’s REXULTI antipsychotic (brexpiprazole) tablets infringe five of its patents.
Generics
Israel imports patented antivirals for treating COVID-19
24 March 2020   Israel has approved generic versions of an HIV antiviral owned by AbbVie for use in treating coronavirus, despite the company still holding patent protection and doubts over its effectiveness.
Biotechnology
Biotech wins $16.5 million in drug royalties dispute
18 October 2022   Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the multiple sclerosis drug elsewhere.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York